ADMA Biologics (NASDAQ: ADMA) reported Q3 EPS of ($0.48), $0.09 worse than the analyst estimate of ($0.39). Revenue for the quarter came in at $1.85 million versus the consensus estimate of $1.5 million.

For earnings history and earnings-related data on ADMA Biologics (ADMA) click here.